MDX-H210

MDX-H210 is a bispecific, humanized monoclonal antibody designed to target both cytotoxic effector cells and tumor cells overexpressing HER2/neu. It is constructed by chemically crosslinking F(ab') fragments from two monoclonal antibodies—H22, which binds to Fc gamma receptor I (FcγRI or CD64) on immune effector cells such as monocytes/macrophages and granulocytes, and 520C9, which targets the HER2/neu proto-oncogene product on tumor cells. By simultaneously binding these two targets, MDX-H210 facilitates antibody-dependent cell-mediated cytotoxicity (ADCC), promoting the lysis of HER2-positive cancer cells by recruiting immune effector functions even in the presence of high serum immunoglobulin concentrations. The drug was developed primarily for use in cancers that overexpress HER2/neu, including breast cancer and prostate cancer. Clinical studies demonstrated biological activity and acceptable toxicity profiles when used alone or in combination with agents like G-CSF or GM-CSF; however, development was discontinued after early-phase trials[1][2][3][4][5].

Other names

bispecific antibody mdx-h210anti-breast-cancer-triggeranti-ovary-cancer-trigger